Innoviva, Inc.

INVA · XNAS

CIK 1080014fmd_0QE2MAH37WN241REDEJ3HKMGVKManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	134	217	261	261	337	392	331	310	359	411
Total interest income	–	–	–	6	2	2	6	16	19	21
Net interest income	–	–	–	(13)	(17)	(17)	(9)	(3)	(3)	4
Realized investment gains (losses)	–	–	0	0	50	91	–	–	–	–
Gross profit	–	–	–	–	–	–	–	246	296	308
Research and development	1	1	0	0	2	1	41	34	14	31
Selling, general and administrative	–	–	–	–	14	16	64	98	116	113
Total operating expenses	25	34	23	15	16	17	–	132	129	144
Operating income	109	184	238	246	321	375	–	114	167	164
Interest expense	52	44	24	19	18	19	16	19	22	17
Other non-operating income (expense)	2	(7)	(6)	(0)	(0)	(4)	(3)	(5)	(3)	(3)
Income before taxes	60	134	210	233	354	445	287	194	37	327
Income tax expense	0	0	(196)	42	60	76	67	14	14	56
Net income from continuing operations	60	134	406	191	294	369	220	180	23	271
Net income	60	134	406	191	294	369	220	180	23	271
Net income to common shareholders	60	134	395	157	224	266	214	180	23	271